← Back to Search

Growth Factor

PANVAC™-VF Vaccine for Pancreatic Cancer

Phase 3
Waitlist Available
Research Sponsored by Therion Biologics Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance status 0-1
Patient has metastatic (Stage IV) disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing a new cancer drug combo vs. standard care to see if it is more effective.

Who is the study for?
This trial is for adults over 18 with Stage IV pancreatic cancer who have not responded to a gemcitabine-based treatment. They must be in good physical condition (ECOG status 0-1) and vaccinated against smallpox. People can't join if they've had recent radiation, other immunotherapies or steroids, significant heart issues, or are HIV or hepatitis B/C positive.Check my eligibility
What is being tested?
The study tests the PANVAC-VF vaccine combined with GM-CSF against either supportive care or palliative chemotherapy to see which is safer and more effective for treating metastatic pancreatic cancer after failure of prior chemotherapy.See study design
What are the potential side effects?
Possible side effects include reactions at the injection site, flu-like symptoms such as fever and chills, fatigue, nausea, and potential immune-related complications due to stimulation by the vaccine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
My cancer has spread to other parts of my body.
Select...
I am over 18 and have been vaccinated against smallpox.
Select...
My diagnosis is pancreatic cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Therion Biologics CorporationLead Sponsor
1 Previous Clinical Trials
120 Total Patients Enrolled

Media Library

Granulocyte-macrophage colony-stimulating factor (GM-CSF) (Growth Factor) Clinical Trial Eligibility Overview. Trial Name: NCT00088660 — Phase 3
Pancreatic Cancer Research Study Groups:
Pancreatic Cancer Clinical Trial 2023: Granulocyte-macrophage colony-stimulating factor (GM-CSF) Highlights & Side Effects. Trial Name: NCT00088660 — Phase 3
Granulocyte-macrophage colony-stimulating factor (GM-CSF) (Growth Factor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00088660 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are the volunteers in this experiment of age 18 or older?

"This study is only open to patients aged 18 years or younger. There are 16 clinical trials currently recruiting for this age group and 722 trials for patients over the age of 65."

Answered by AI

Who meets the requirements to be a part of this research project?

"This study is looking for 250 individuals that have been diagnosed with pancreatic cancer. These patients must be 18 years or older and have failed a gemcitabine-containing chemotherapy within the last 3 months. Furthermore, these participants' ECOG performance status cannot exceed 1."

Answered by AI

Can new patients still sign up for this clinical trial?

"According to the latest information available on clinicaltrials.gov, this study is no longer recruiting patients. Although it has not been updated in some time, the fact that 725 other studies are currently looking for participants suggests that there are plenty of opportunities to get involved in cutting-edge medical research."

Answered by AI

Could you tell us how many different hospitals are participating in this research project?

"As of right now, this study is looking for participants at 62 different sites. While some locations are in San Diego, Norwalk and Kettering, there are also many other options closer to where you might live. Reducing travel demands is an important consideration when selecting a clinic to participate in."

Answered by AI

Could you please outline the risks associated with this treatment plan?

"There is some efficacy data and multiple rounds of safety data, so this treatment received a score of 3."

Answered by AI

Who else is applying?

What state do they live in?
Idaho
How old are they?
65+
What site did they apply to?
St. Luke's Mountain States Tumor Institute
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen
2004. "PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00088660.
All > Mci
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top